clinical trial · NCT07170150
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
Alzheimers DiseaseTrontinemabPlacebo
brief summary
The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment \[MCI\] to mild dementia due to AD).
started
Nov 12, 2025
primary completion
Feb 16, 2028
completion
Feb 16, 2028
last updated
Sep 25, 2026
official title
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease (MCI to Mild Dementia Due to AD)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol